

Francasco Patti

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5708951/francasco-patti-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

<div>305</div> <div>papers</div>	<div>7,965</div> <div>citations</div>	<div>44</div> <div>h-index</div>	<div>77</div> <div>g-index</div>
<div>330</div> <div>ext. papers</div>	<div>9,878</div> <div>ext. citations</div>	<div>4.9</div> <div>avg, IF</div>	<div>5.81</div> <div>L-index</div>

#	Paper	IF	Citations
305	Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022 , 9,	9.1	4
304	Comparing natural history of early and late onset pediatric multiple sclerosis.. <i>Annals of Neurology</i> , 2022 ,	9.4	2
303	Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 57, 103385	4	1
302	COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022 , 9,	9.1	17
301	Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 58, 103489	4	1
300	Reliability of televisits for patients with mild relapsing-remitting multiple sclerosis in the COVID-19 era.. <i>Neurological Sciences</i> , 2022 , 1	3.5	0
299	Factors driving delayed time to multiple sclerosis diagnosis: Results from a population-based study.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 57, 103361	4	0
298	Immunological Subsets Characterization in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis.. <i>Frontiers in Immunology</i> , 2022 , 13, 819136	8.4	1
297	Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221079598	5	1
296	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221084577	5	0
295	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset.. <i>Neurology</i> , 2022 , 98, e1626-e1636	6.5	0
294	Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.. <i>Lancet Neurology</i> , 2022 ,	24.1	4
293	Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study. <i>International Journal of Environmental Research and Public Health</i> , 2022 , 19, 6069	4.6	0
292	A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 103909	4	0
291	Oral norgestrel acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1458-1463	5	3
290	An update on idiopathic intracranial hypertension in adults: a look at pathophysiology, diagnostic approach and management. <i>Journal of Neurology</i> , 2021 , 268, 3249-3268	5.5	14
289	The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2021 ,	6	1

288	Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series. <i>BMC Neurology</i> , 2021 , 21, 462	3.1	1
287	Spinal needle and post-dural puncture headache. <i>Neurological Sciences</i> , 2021 , 43, 1467	3.5	0
286	Multiple Sclerosis, COVID-19 and Vaccines: Making the Point. <i>Neurology and Therapy</i> , 2021 , 10, 627-649	4.6	1
285	Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a. <i>Neurology</i> , 2021 , 96, e214-e227	6.5	2
284	Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results. <i>Neurological Sciences</i> , 2021 , 42, 2837-2845	3.5	2
283	Living with severe multiple sclerosis: Cost-effectiveness of a palliative care intervention and cost of illness study. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 49, 102756	4	
282	Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. <i>Neurology</i> , 2021 ,	6.5	8
281	Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study. <i>Neurotherapeutics</i> , 2021 , 18, 1166-1174	6.4	10
280	Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 2284-2287	5	4
279	Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis. <i>JAMA Neurology</i> , 2021 , 78, 414-425	17.2	23
278	Early-Onset Alcohol Dependence and Multiple Sclerosis: Diagnostic Challenges. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	2
277	PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. <i>Journal of Neurology</i> , 2021 , 1	5.5	3
276	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211023365	5	2
275	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2021 , 78, 726-735	17.2	4
274	Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration. <i>Journal of Neurology</i> , 2021 , 1	5.5	1
273	The Dysphagia in Multiple Sclerosis Questionnaire Correlates with Fiber-Optic Endoscopic Examination for Detecting Swallowing Deficits in MS. <i>Dysphagia</i> , 2021 , 36, 192-197	3.7	2
272	Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. <i>European Journal of Neurology</i> , 2021 , 28, 567-578	6	4
271	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 430-438	5	1

- 270 The Contribution of Illness Beliefs, Coping Strategies, and Social Support to Perceived Physical Health and Fatigue in Multiple Sclerosis. *Journal of Clinical Psychology in Medical Settings*, **2021**, 28, 149-160 9
- 269 Exploring polypharmacy phenomenon in newly diagnosed relapsing-remitting multiple sclerosis: a cohort ambispective single-centre study. *Therapeutic Advances in Chronic Disease*, **2021**, 12, 2040622320983125
- 268 Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. *Therapeutic Advances in Neurological Disorders*, **2021**, 14, 17562864211019574
- 267 Determinants of therapeutic lag in multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 27, 1838-1851 5 2
- 266 Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. *Annals of Neurology*, **2021**, 89, 780-789 9.4 189
- 265 Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. *Neurotherapeutics*, **2021**, 18, 905-919 6.4 6
- 264 Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD. *Annals of Neurology*, **2021**, 89, 1088-1098 9.4 13
- 263 Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus. *Journal of Neurology*, **2021**, 268, 1540-1543 5.5 3
- 262 First-line therapies in late-onset multiple sclerosis: An Italian registry study. *European Journal of Neurology*, **2021**, 28, 4117-4123 6 5
- 261 SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. *Multiple Sclerosis Journal*, **2021**, 13524585211035318 5 21
- 260 DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. *Annals of Clinical and Translational Neurology*, **2021**, 8, 1738-1744 5.3 36
- 259 Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study. *BMC Neurology*, **2021**, 21, 324 3.1 4
- 258 Job satisfaction among physicians and nurses involved in the management of multiple sclerosis: the role of happiness and meaning at work. *Neurological Sciences*, **2021**, 1 3.5 2
- 257 Study protocol on advance care planning in multiple sclerosis (ConCure-SM): intervention construction and multicentre feasibility trial. *BMJ Open*, **2021**, 11, e052012 3 0
- 256 Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study. *Muscle and Nerve*, **2021**, 64, 662-669 3.4 1
- 255 Italian translation and psychometric validation of the ABILHAND-26 and its correlation with upper limb objective and subjective measures in multiple sclerosis subjects. *Multiple Sclerosis and Related Disorders*, **2021**, 55, 103160 4
- 254 Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. *Journal of the Neurological Sciences*, **2021**, 430, 118067 3.2 0
- 253 Rituximab for the treatment of multiple sclerosis: a review. *Journal of Neurology*, **2021**, 1 5.5 26

252	Toxoplasma gondii and multiple sclerosis: a population-based case-control study. <i>Scientific Reports</i> , 2020 , 10, 18855	4.9	4
251	BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECT. <i>Patient Preference and Adherence</i> , 2020 , 14, 771-779	2.4	3
250	Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis patients. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 1449-1454	4	5
249	EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis. <i>Journal of Palliative Medicine</i> , 2020 , 23, 1426-1443	2.2	4
248	EAN guideline on palliative care of people with severe, progressive multiple sclerosis. <i>European Journal of Neurology</i> , 2020 , 27, 1510-1529	6	11
247	Palliative care in multiple sclerosis: European guideline. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1009-1011	5	0
246	Efficacy of levetiracetam on upper limb movement in multiple sclerosis patients with cerebellar signs: a multicenter double-blind, placebo-controlled, crossover study. <i>European Journal of Neurology</i> , 2020 , 27, 2209-2216	6	4
245	Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis. <i>Journal of Neurology</i> , 2020 , 267, 3008-3020	5.5	12
244	Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience. <i>Frontiers in Neurology</i> , 2020 , 11, 105	4.1	7
243	Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study. <i>Journal of Neurology</i> , 2020 , 267, 1812-1823	5.5	1
242	Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis. <i>Clinical Drug Investigation</i> , 2020 , 40, 319-326	3.2	2
241	CSF neurotoxic metals/metalloids levels in amyotrophic lateral sclerosis patients: comparison between bulbar and spinal onset. <i>Environmental Research</i> , 2020 , 188, 109820	7.9	7
240	Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). <i>Therapeutic Advances in Neurological Disorders</i> , 2020 , 13, 1756286420922685	6.6	11
239	Box and block test, hand grip strength and nine-hole peg test: correlations between three upper limb objective measures in multiple sclerosis. <i>European Journal of Neurology</i> , 2020 , 27, 2523-2530	6	6
238	Italian validation of the caregiving tasks in multiple sclerosis scale (CTiMSS). <i>Neurological Sciences</i> , 2020 , 41, 1881-1889	3.5	
237	Italian translation and psychometric validation of the Manual Ability Measure-36 (MAM-36) and its correlation with an objective measure of upper limb function in patients with multiple sclerosis. <i>Neurological Sciences</i> , 2020 , 41, 1539-1546	3.5	4
236	Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment. <i>Expert Review of Neurotherapeutics</i> , 2020 , 20, 771-782	4.3	3
235	An update on the pharmacological management of pain in patients with multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 2249-2263	4	3

234	Listening to the neurological teams for multiple sclerosis: the SMART project. <i>Neurological Sciences</i> , 2020 , 41, 2231-2240	3.5	5
233	Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab. <i>CNS Drugs</i> , 2020 , 34, 535-543	6.7	3
232	Environmental and Occupational Risk Factors of Amyotrophic Lateral Sclerosis: A Population-Based Case-Control Study. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	21
231	Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study. <i>Neurological Sciences</i> , 2020 , 41, 2905-2913	3.5	3
230	Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study). <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 42, 102124	4	5
229	Clinical and Lifestyle Factors and Risk of Amyotrophic Lateral Sclerosis: A Population-Based Case-Control Study. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	22
228	A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon- β in multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 40, 101952	4	
227	Italian consensus on treatment of spasticity in multiple sclerosis. <i>European Journal of Neurology</i> , 2020 , 27, 445-453	6	9
226	The caring experience in multiple sclerosis: Caregiving tasks, coping strategies and psychological well-being. <i>Health and Social Care in the Community</i> , 2020 , 28, 236-246	2.6	9
225	An "all-wheel drive" proposal to accelerate clinical research in common and rare neurological diseases. <i>Neurological Sciences</i> , 2020 , 41, 789-793	3.5	
224	Prevalence of dysphagia in a consecutive cohort of subjects with MS using fibre-optic endoscopy. <i>Neurological Sciences</i> , 2020 , 41, 1075-1079	3.5	4
223	Incidence of multiple sclerosis in the province of Catania. A geo-epidemiological study. <i>Environmental Research</i> , 2020 , 182, 109022	7.9	7
222	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 38, 101868	4	15
221	Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 1297-1303	5.5	13
220	Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 46, 102492	4	8
219	Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 46, 102561	4	11
218	Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 914-920	5.5	1
217	Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study. <i>Frontiers in Neurology</i> , 2020 , 11, 756	4.1	4

216	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020 , 143, 2742-2756	11.2	8
215	Comparing 16 Different Dual-Tasking Paradigms in Individuals With Multiple Sclerosis and Healthy Controls: Working Memory Tasks Indicate Cognitive-Motor Interference. <i>Frontiers in Neurology</i> , 2020 , 11, 918	4.1	4
214	Reply to Comment on "Environmental and Occupational Risk Factors of Amyotrophic Lateral Sclerosis: A Population-Based Case-Control Study". <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	1
213	Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. <i>Brain</i> , 2020 , 143, 3013-3024	11.2	20
212	Objective evaluation of Nintendo Wii Fit Plus balance program training on postural stability in Multiple Sclerosis patients: a pilot study. <i>International Journal of Rehabilitation Research</i> , 2020 , 43, 199-205	1.8	2
211	Lack of association between and multiple sclerosis: A population-based case-control study. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 258-259	5	3
210	Illness perceptions and psychological adjustment among persons with multiple sclerosis: the mediating role of coping strategies and social support. <i>Disability and Rehabilitation</i> , 2020 , 42, 3780-3792	2.4	12
209	Lack of evidence for Toxocara infection in Italian myelitis patients. <i>Neurological Sciences</i> , 2020 , 41, 239-244	1.5	2
208	Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany. <i>Frontiers in Neurology</i> , 2019 , 10, 916	4.1	10
207	Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. <i>Journal of Neurology</i> , 2019 , 266, 3098-3107	5.5	1
206	Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod. <i>Journal of the Neurological Sciences</i> , 2019 , 405, 116423	3.2	4
205	The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis. <i>Cells</i> , 2019 , 8,	7.9	18
204	Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies. <i>Neurodegenerative Disease Management</i> , 2019 , 9, 3-7	2.8	1
203	Pharmacoeconomics of synthetic therapies for multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 1331-1340	4	6
202	Amyotrophic lateral sclerosis spatial epidemiology in the Mount Etna region, Italy. <i>European Journal of Neurology</i> , 2019 , 26, e90-e91	6	4
201	Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives. <i>Autoimmunity Reviews</i> , 2019 , 18, 665-672	13.6	21
200	Aging with multiple sclerosis: prevalence and profile of cognitive impairment. <i>Neurological Sciences</i> , 2019 , 40, 1651-1657	3.5	24
199	Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort. <i>Frontiers in Neurology</i> , 2019 , 10, 337	4.1	15

198	Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study. <i>Neurological Sciences</i> , 2019 , 40, 1383-1391	3.5	4
197	Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis. <i>European Journal of Neurology</i> , 2019 , 26, 41-50	6	14
196	eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 856-866	5	5
195	Prevalence and Incidence of Multiple Sclerosis in the City of Biancavilla. <i>Neuroepidemiology</i> , 2019 , 53, 108-114	5.4	3
194	An update on the safety of treating relapsing-remitting multiple sclerosis. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 925-948	4.1	8
193	Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , 2019 , 18, 845-856	24.1	56
192	Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study. <i>Autoimmunity Reviews</i> , 2019 , 18, 102365	13.6	65
191	Examining the validity of the multiple-sclerosis walking scale-12 with Rasch analysis: Results from an Italian study. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 36, 101400	4	4
190	Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. <i>New England Journal of Medicine</i> , 2019 , 381, 2114-2124	59.2	212
189	Retinal Nerve Fiber Layer Thickness and Higher Relapse Frequency May Predict Poor Recovery after Optic Neuritis in MS Patients. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	10
188	Management of dysphagia in multiple sclerosis: current best practice. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019 , 13, 47-54	4.2	10
187	The Italian multiple sclerosis register. <i>Neurological Sciences</i> , 2019 , 40, 155-165	3.5	42
186	Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 27, 324-326	4	22
185	Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience. <i>Journal of Neurology</i> , 2019 , 266, 411-416	5.5	16
184	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 591-600	5	9
183	Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 399-407	5	20
182	Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 531-536	3.8	2
181	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. <i>Neurology</i> , 2018 , 90, e823-e831	6.5	54

180	Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria. <i>Journal of Neurology</i> , 2018 , 265, 828-835	5.5	27
179	Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 341-352	5.5	1
178	Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 167-174	5	14
177	Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 663-674	5	24
176	Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1234-1242	5	24
175	Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study. <i>European Journal of Neurology</i> , 2018 , 25, 1425-1431	6	24
174	Participant perspectives of a home-based palliative approach for people with severe multiple sclerosis: A qualitative study. <i>PLoS ONE</i> , 2018 , 13, e0200532	3.7	8
173	Botulinum Toxin A for Sialorrhoea Associated with Neurological Disorders: Evaluation of the Relationship between Effect of Treatment and the Number of Glands Treated. <i>Toxins</i> , 2018 , 10,	4.9	21
172	Authors' Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl. <i>Neurology and Therapy</i> , 2018 , 7, 391-393	4.6	
171	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. <i>Journal of Neurology</i> , 2018 , 265, 2851-2860	5.5	24
170	Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience. <i>Therapeutic Advances in Neurological Disorders</i> , 2018 , 11, 1756286418796404	6.6	20
169	Static postural control disturbances among the different multiple sclerosis phenotypes: A Neurocom Balance Manager evaluation study. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 26, 46-51	4	3
168	Cognitive assessment in multiple sclerosis-an Italian consensus. <i>Neurological Sciences</i> , 2018 , 39, 1317-1324	3.5	18
167	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. <i>Journal of the Neurological Sciences</i> , 2018 , 391, 72-76	3.2	11
166	Cognitive-motor dual-task interference: A systematic review of neural correlates. <i>Neuroscience and Biobehavioral Reviews</i> , 2017 , 75, 348-360	9	97
165	Multiple sclerosis and amyotrophic lateral sclerosis: a human leukocyte antigen challenge. <i>Neurological Sciences</i> , 2017 , 38, 1501-1503	3.5	4
164	Prognostic indicators in pediatric clinically isolated syndrome. <i>Annals of Neurology</i> , 2017 , 81, 729-739	9.4	26
163	Can new chemical therapies improve the management of multiple sclerosis in children?. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 45-55	4	1

162	Computer-assisted cognitive rehabilitation on freezing of gait in Parkinson's disease: A pilot study. <i>Neuroscience Letters</i> , 2017 , 654, 38-41	3.3	10
161	Migraine causes retinal and choroidal structural changes: evaluation with ocular coherence tomography. <i>Journal of Neurology</i> , 2017 , 264, 494-502	5.5	24
160	Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). <i>Journal of Neurology</i> , 2017 , 264, 2436-2449	5.5	35
159	The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study. <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 17, 154-171	4	2
158	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. <i>Lancet Neurology</i> , 2017 , 16, 976-986	24.1	278
157	Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study). <i>PLoS ONE</i> , 2017 , 12, e0180651	3.7	20
156	Pesticide exposure assessed through agricultural crop proximity and risk of amyotrophic lateral sclerosis. <i>Environmental Health</i> , 2017 , 16, 91	6	25
155	A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon- β using RebiSmart [®] the FUTURE study. <i>Neurological Sciences</i> , 2017 , 38, 1999-2005	3.5	9
154	Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. <i>Neurological Sciences</i> , 2017 , 38, 1849-1858	3.5	19
153	A Comprehensive Review on Copemyl. <i>Neurology and Therapy</i> , 2017 , 6, 161-173	4.6	6
152	Magnetic fields exposure from high-voltage power lines and risk of amyotrophic lateral sclerosis in two Italian populations. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017 , 18, 583-589	3.6	9
151	Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1258-1267	5	136
150	Palliative care in progressive multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2017 , 17, 123-127	4.3	2
149	Beyond Disease: Happiness, Goals, and Meanings among Persons with Multiple Sclerosis and Their Caregivers. <i>Frontiers in Psychology</i> , 2017 , 8, 2216	3.4	19
148	Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers. <i>Journal of Clinical Psychology in Medical Settings</i> , 2016 , 23, 33-52	2	27
147	When the word doesn't come out: A synthetic overview of dysarthria. <i>Journal of the Neurological Sciences</i> , 2016 , 369, 354-360	3.2	9
146	Extensive bilateral striopallidodentate calcinosis: a 50 years history of hypoparathyroidism presenting like a parkinsonian syndrome. <i>Journal of Neurology</i> , 2016 , 263, 1876-9	5.5	6
145	The heritage of glatiramer acetate and its use in multiple sclerosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2016 , 1,	0	8

144	The epidemiology of amyotrophic lateral sclerosis in the Mount Etna region: a possible pathogenic role of volcanogenic metals. <i>European Journal of Neurology</i> , 2016 , 23, 964-72	6	25
143	Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study. <i>Journal of Neurology</i> , 2016 , 263, 1802-9	5.5	13
142	Low quality of life and psychological wellbeing contrast with moderate perceived burden in carers of people with severe multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2016 , 366, 139-145	3.2	17
141	Inpatient versus outpatient rehabilitation for multiple sclerosis patients: effects on disability and quality of life. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2016 , 1,	0	3
140	Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. <i>Journal of Neurology</i> , 2016 , 263, 1727-35	5.5	35
139	Expression of DNA methylation genes in secondary progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2016 , 290, 66-9	3.5	16
138	Diagnostic tools for assessment of urinary dysfunction in MS patients without urinary disturbances. <i>Neurological Sciences</i> , 2016 , 37, 437-42	3.5	2
137	The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1741-1749	5	19
136	Health Authorities Data Collection of THC:CBD Oromucosal Spray (L'Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years. <i>European Neurology</i> , 2016 , 75 Suppl 1, 9-12	2.1	7
135	Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 581-9	5	16
134	Use of herbal remedies by multiple sclerosis patients: a nation-wide survey in Italy. <i>Neurological Sciences</i> , 2016 , 37, 613-22	3.5	9
133	Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory. <i>PLoS ONE</i> , 2016 , 11, e0153466	3.7	20
132	The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retrospective Study. <i>PLoS ONE</i> , 2016 , 11, e0157721	3.7	3
131	Disability may influence patient willingness to participate in decision making on first-line therapy in multiple sclerosis. <i>Functional Neurology</i> , 2016 , 31, 21-3	2.2	11
130	Offspring Number Does Not Influence Reaching the Disability's Milestones in Multiple Sclerosis: A Seven-Year Follow-Up Study. <i>International Journal of Molecular Sciences</i> , 2016 , 17, 234	6.3	10
129	A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	19
128	Depressive Symptoms Correlate with Disability and Disease Course in Multiple Sclerosis Patients: An Italian Multi-Center Study Using the Beck Depression Inventory. <i>PLoS ONE</i> , 2016 , 11, e0160261	3.7	34
127	Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 944-51	5.5	63

126	Personalized therapy in multiple sclerosis: state of art and future perspectives. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016 , 1, 353-360	1.6	2
125	Ataxia with vitamin E deficiency caused by a new compound heterozygous mutation. <i>Neurological Sciences</i> , 2016 , 37, 1571-2	3.5	0
124	Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories. <i>Quality of Life Research</i> , 2016 , 25, 2755-2763	3.7	7
123	Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs. <i>Drug Safety</i> , 2016 , 39, 1163-1174	5.1	30
122	Risk factors in multiple sclerosis: a population-based case-control study in Sicily. Background and methods. <i>Neurological Sciences</i> , 2016 , 37, 1931-1937	3.5	9
121	Analysis of genes, pathways and networks involved in disease severity and age at onset in primary-progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1431-42	5	18
120	Prevalence and incidence of cognitive impairment in multiple sclerosis: a population-based survey in Catania, Sicily. <i>Journal of Neurology</i> , 2015 , 262, 923-30	5.5	28
119	A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 1157-68	4.1	3
118	Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal. <i>Expert Review of Neurotherapeutics</i> , 2015 , 15, 803-24	4.3	27
117	Multiple sclerosis: getting personal with induced pluripotent stem cells. <i>Cell Death and Disease</i> , 2015 , 6, e1806	9.8	13
116	Measuring the cost of cognitive-motor dual tasking during walking in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 123-31	5	86
115	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. <i>Brain</i> , 2015 , 138, 3275-86	11.2	63
114	Relationship between urodynamic findings and sexual function in multiple sclerosis patients with lower urinary tract dysfunction. <i>European Journal of Neurology</i> , 2015 , 22, 485-92	6	9
113	Restless legs syndrome and multiple sclerosis: a population based case-control study in Catania, Sicily. <i>European Journal of Neurology</i> , 2015 , 22, 1018-21	6	16
112	Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report. <i>BMC Neurology</i> , 2015 , 15, 252	3.1	9
111	Lesion load may predict long-term cognitive dysfunction in multiple sclerosis patients. <i>PLoS ONE</i> , 2015 , 10, e0120754	3.7	24
110	Italian validation of the 12-item multiple sclerosis walking scale. <i>Multiple Sclerosis International</i> , 2015 , 2015, 540828	1.1	10
109	Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives. <i>Expert Review of Neurotherapeutics</i> , 2015 , 15, 251-68	4.3	4

108	Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled trial. <i>Trials</i> , 2015 , 16, 184	2.8	24
107	Association Between the Neurogenic Bladder Symptom Score and Urodynamic Examination in Multiple Sclerosis Patients With Lower Urinary Tract Dysfunction. <i>International Neuourology Journal</i> , 2015 , 19, 272-7	2.6	12
106	Guidelines on the clinical use for the detection of neutralizing antibodies (NABs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. <i>Neurological Sciences</i> , 2014 , 35, 307-16	3.5	28
105	Pregnancy outcomes in multiple sclerosis patients previously treated with cyclophosphamide. <i>Acta Neurologica Scandinavica</i> , 2014 , 130, e41-4	3.8	4
104	Genetic burden of common variants in progressive and bout-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 802-11	5	10
103	Neuropsychological features in childhood and juvenile multiple sclerosis: five-year follow-up. <i>Neurology</i> , 2014 , 83, 1432-8	6.5	78
102	Subcortical deep gray matter pathology in patients with multiple sclerosis is associated with white matter lesion burden and atrophy but not with cortical atrophy: a diffusion tensor MRI study. <i>American Journal of Neuroradiology</i> , 2014 , 35, 912-9	4.4	32
101	Is the basic trunk control recovery different between stroke patients with right and left hemiparesis?. <i>NeuroRehabilitation</i> , 2014 , 35, 215-20	2	4
100	The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals. <i>Journal of the Neurological Sciences</i> , 2014 , 337, 67-73	3.2	28
99	Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. <i>BMC Neurology</i> , 2014 , 14, 114	3.1	22
98	Interferon-beta-1a treatment has a positive effect on quality of life of relapsing-remitting multiple sclerosis: results from a longitudinal study. <i>Journal of the Neurological Sciences</i> , 2014 , 337, 180-5	3.2	7
97	Diffusion tensor MRI alterations of subcortical deep gray matter in clinically isolated syndrome. <i>Journal of the Neurological Sciences</i> , 2014 , 338, 128-34	3.2	16
96	Unmet needs of people with severe multiple sclerosis and their carers: qualitative findings for a home-based intervention. <i>PLoS ONE</i> , 2014 , 9, e109679	3.7	53
95	Fostering adherence to injectable disease-modifying therapies in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2014 , 14, 1029-42	4.3	42
94	Symptoms, prevalence and impact of multiple sclerosis in younger patients: a multinational survey. <i>Neuroepidemiology</i> , 2014 , 42, 211-8	5.4	24
93	Determinants of sexual impairment in multiple sclerosis in male and female patients with lower urinary tract dysfunction: results from an Italian cross-sectional study. <i>Journal of Sexual Medicine</i> , 2014 , 11, 2406-13	1.1	20
92	Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 845-50	5.5	48
91	Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 220-6	5	23

90	Gray matters in multiple sclerosis: cognitive impairment and structural MRI. <i>Multiple Sclerosis International</i> , 2014 , 2014, 609694	1.1	31
89	The Rao's Brief Repeatable Battery version B: normative values with age, education and gender corrections in an Italian population. <i>Neurological Sciences</i> , 2014 , 35, 79-82	3.5	22
88	Heme oxygenase-1 expression in peripheral blood mononuclear cells correlates with disease activity in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2013 , 261, 82-6	3.5	36
87	Cognitive impairment and "invisible symptoms" are not associated with CCSVI in MS. <i>BMC Neurology</i> , 2013 , 13, 97	3.1	4
86	The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013 , 9, 1349-59	5.5	17
85	Prevalence of patient-reported dysphagia in multiple sclerosis patients: an Italian multicenter study (using the DYMUS questionnaire). <i>Journal of the Neurological Sciences</i> , 2013 , 331, 94-7	3.2	39
84	Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. <i>Neurological Sciences</i> , 2013 , 34, 1633-7	3.5	17
83	Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1508-17	5	35
82	Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study. <i>Clinical Neuropharmacology</i> , 2013 , 36, 114-6	1.4	24
81	Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 961-3	5	14
80	Subcutaneous interferon β 1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. <i>PLoS ONE</i> , 2013 , 8, e74117	3.7	42
79	Multiple Sclerosis in the Mount Etna region: possible role of volcanogenic trace elements. <i>PLoS ONE</i> , 2013 , 8, e74259	3.7	15
78	Aspetti che influenzano l'adesione alla terapia 2013 , 81-87		
77	Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β 1a: results from the COGIMUS (COGNitive Impairment in Multiple Sclerosis) study (II). <i>Quality of Life Research</i> , 2012 , 21, 1111-21	3.7	7
76	Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. <i>BMC Neurology</i> , 2012 , 12, 124	3.1	72
75	Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. <i>BMC Neurology</i> , 2012 , 12, 165	3.1	66
74	Treatment of cognitive impairment in patients with multiple sclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 1679-99	5.9	22
73	Multiple sclerosis and CCSVI: a population-based case control study. <i>PLoS ONE</i> , 2012 , 7, e41227	3.7	21

72	Frequency and severity of headache is worsened by Interferon- β therapy in patients with multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2012 , 125, 91-5	3.8	27
71	Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 329-34	5	65
70	The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. <i>European Journal of Neurology</i> , 2011 , 18, 69-77	6	250
69	Botulinum toxin improves dysphagia associated with multiple sclerosis. <i>European Journal of Neurology</i> , 2011 , 18, 486-90	6	36
68	Clinical features of Sjogren's syndrome in patients with multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2011 , 124, 109-14	3.8	16
67	Multiple sclerosis in Italy: cost-of-illness study. <i>Neurological Sciences</i> , 2011 , 32, 787-94	3.5	29
66	Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. <i>Neurological Sciences</i> , 2011 , 32, 1223-31	3.5	33
65	Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β 1a in the COGNITIVE Impairment in Multiple Sclerosis (COGIMUS) study. <i>BMC Neurology</i> , 2011 , 11, 125	3.1	11
64	Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 1355-9	5.5	17
63	Increasing frequency of multiple sclerosis in Catania, Sicily: a 30-year survey. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 273-80	5	35
62	Sporadic motor neuron disease in a familial novel SOD1 mutation: incomplete penetrance or chance association?. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2011 , 12, 220-2		6
61	Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis. <i>Autoimmune Diseases</i> , 2011 , 2011, 961702	2.9	18
60	Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGNITIVE Impairment in Multiple Sclerosis) study. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 991-1001	5	39
59	Breastfeeding is not related to postpartum relapses in multiple sclerosis. <i>Neurology</i> , 2011 , 77, 145-50	6.5	116
58	Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis. <i>Clinical and Experimental Immunology</i> , 2010 , 159, 159-68	6.2	19
57	Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. <i>Patient Preference and Adherence</i> , 2010 , 4, 1-9	2.4	126
56	Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. <i>Neurology</i> , 2010 , 75, 1134-40	6.5	170
55	Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. <i>Neurology</i> , 2010 , 75, 619-25	6.5	78

54	Pregnancy and fetal outcomes after interferon- β exposure in multiple sclerosis. <i>Neurology</i> , 2010 , 75, 1794-802	6.5	121
53	Outcome of psychiatric symptoms presenting at onset of multiple sclerosis: a retrospective study. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 742-8	5	49
52	Mutation analysis of the SPG4 gene in Italian patients with pure and complicated forms of spastic paraplegia. <i>Journal of the Neurological Sciences</i> , 2010 , 288, 96-100	3.2	23
51	Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 68-77	5	75
50	Psychosocial issue in children and adolescents with multiple sclerosis. <i>Neurological Sciences</i> , 2010 , 31, 467-70	3.5	36
49	Treatment options of cognitive impairment in multiple sclerosis. <i>Neurological Sciences</i> , 2010 , 31, S265-9	3.5	21
48	Quality of Life in Patients Affected by Multiple Sclerosis: A Systematic Review 2010 , 3769-3783		1
47	Psychometric properties of the Italian version of the Guy's Neurological Disability Scale. <i>Functional Neurology</i> , 2010 , 25, 223-33	2.2	3
46	The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 620-6	5	44
45	Cognitive impairment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 2-8	5	107
44	Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 779-88	5	141
43	Subcutaneous Interferon Beta-1a Has a Positive Effect on Cognitive Performance in Mildly Disabled Patients with Relapsing-Remitting Multiple Sclerosis: 2-Year Results from the COGIMUS Study. <i>Therapeutic Advances in Neurological Disorders</i> , 2009 , 2, 67-77	6.6	10
42	A possible spatial and temporal cluster of multiple sclerosis in the town of Linguaglossa, Sicily: an update. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 129-30	5	9
41	Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2009 , 66, 513-20	9.4	109
40	Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. <i>Neurological Sciences</i> , 2009 , 30, 193-9	3.5	58
39	An exploration of anger phenomenology in multiple sclerosis. <i>European Journal of Neurology</i> , 2009 , 16, 1312-7	6	11
38	Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment. <i>Journal of the Neurological Sciences</i> , 2009 , 286, 109-13	3.2	22
37	Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab. <i>ClinicoEconomics and Outcomes Research</i> , 2009 , 1, 45-51	1.7	1

36	Validation of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis. <i>Functional Neurology</i> , 2009 , 24, 159-62	2.2	37
35	Headache and multiple sclerosis: a population-based case-control study in Catania, Sicily. <i>Cephalalgia</i> , 2008 , 28, 1163-9	6.1	49
34	The DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2008 , 269, 49-53	3.2	63
33	Cognitive and psychosocial features of childhood and juvenile MS. <i>Neurology</i> , 2008 , 70, 1891-7	6.5	209
32	Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis?. <i>Journal of Neurology</i> , 2008 , 255, 1250-3	5.5	59
31	Predictors of quality of life among patients with multiple sclerosis: an Italian cross-sectional study. <i>Journal of the Neurological Sciences</i> , 2007 , 252, 121-9	3.2	35
30	Caregiver quality of life in multiple sclerosis: a multicentre Italian study. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 412-9	5	68
29	Effects of education level and employment status on HRQoL in early relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 783-91	5	88
28	The Rao's Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 787-93	5	273
27	Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study. <i>Acta Neurologica Scandinavica</i> , 2006 , 113, 241-7	3.8	25
26	Pharmacologic management of spasticity in multiple sclerosis. <i>Neurological Sciences</i> , 2006 , 27, s310-s315	3.5	3
25	Non-pharmacologic interventions for spasticity associated with multiple sclerosis. <i>Neurological Sciences</i> , 2006 , 27, s316-s319	3.5	2
24	Management of swallowing disorders in multiple sclerosis. <i>Neurological Sciences</i> , 2006 , 27, s338-s340	3.5	9
23	A possible spatial and temporal cluster of multiple sclerosis in the town of Linguaglossa, Sicily. <i>Journal of Neurology</i> , 2005 , 252, 921-5	5.5	18
22	The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up. <i>Journal of Neurology</i> , 2005 , 252, 1255-61	5.5	27
21	Possible increasing risk of multiple sclerosis in Catania, Sicily. <i>Neurology</i> , 2005 , 65, 1259-63	6.5	40
20	Brain atrophy and lesion load in a large population of patients with multiple sclerosis. <i>Neurology</i> , 2005 , 65, 280-5	6.5	126
19	Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 420-4	5	90

18	The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. <i>Neurology</i> , 2004 , 63, 919-21	6.5	221
17	Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. <i>Journal of Neurology</i> , 2004 , 251, 1502-6	5.5	26
16	A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. <i>Journal of the Neurological Sciences</i> , 2004 , 223, 69-71	3.2	23
15	Health-related quality of life and depression in an Italian sample of multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2003 , 211, 55-62	3.2	88
14	Prevalence and incidence of multiple sclerosis in Catania, Sicily. <i>Neurology</i> , 2001 , 56, 62-6	6.5	51
13	Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001 , 71, 404-7	5.5	40
12	Sodium fusidate (fusidin) ameliorates the course of monophasic experimental allergic encephalomyelitis in the Lewis rat. <i>Multiple Sclerosis Journal</i> , 2001 , 7, 101-4	5	7
11	Increased serum levels of interleukin-18 in patients with multiple sclerosis. <i>Neurology</i> , 2001 , 57, 342-4	6.5	75
10	The antiinflammatory cytokine interleukin-13 is not detectable in the circulation of multiple sclerosis patients and is not inducible by interferon-beta1b treatment, that neither modifies its ex vivo secretion from peripheral blood mononuclear cells. <i>Autoimmunity</i> , 2000 , 32, 265-70	3	3
9	Neuropsychological, neuroradiological and clinical findings in multiple sclerosis. A 3 year follow-up study. <i>European Journal of Neurology</i> , 1998 , 5, 283-286	6	26
8	Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b). <i>Clinical and Experimental Immunology</i> , 1998 , 113, 96-9	6.2	63
7	Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment. <i>Cytokine</i> , 1996 , 8, 395-400	4	75
6	Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 1996 , 70, 87-90	3.5	103
5	Drug-induced parkinsonism: prevalence, clinical features and follow-up study in three Sicilian communities. <i>Journal of Neurology</i> , 1996 , 243, 293-295	5.5	2
4	Breakthrough SARS-CoV-2 infections in MS patients on disease modifying therapies		2
3	Disease Modifying Therapies and COVID-19 Severity in Multiple Sclerosis. <i>SSRN Electronic Journal</i> ,	1	26
2	Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. <i>Journal of Neurology</i> ,	5.5	2
1	Patients with multiple sclerosis: a burden and cost of illness study. <i>Journal of Neurology</i> ,	5.5	1

